- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-477/11 P: Order of the Court of 14 May 2012 — Sepracor Pharmaceuticals (Ireland) Ltd v European Commission (Appeals — Regulation (EC) No 726/2004 — Medicinal products for human use — Active substance ‘eszopiclone’ — Marketing authorisation — Procedure — Statement of position by the Commission — Status of ‘new active substance’ — Concept of ‘actionable measure’ )
ECLI:EU:UNKNOWN:62011CB0477
62011CB0477
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 303/6
(Case C-477/11 P) (<a id="ntc1-C_2012303EN.01000601-E0001" href="#ntr1-C_2012303EN.01000601-E0001"> (<span class="super">1</span>)</a>)
(Appeals - Regulation (EC) No 726/2004 - Medicinal products for human use - Active substance ‘eszopiclone’ - Marketing authorisation - Procedure - Statement of position by the Commission - Status of ‘new active substance’ - Concept of ‘actionable measure’)
2012/C 303/10
Language of the case: English
Parties
Appellant: Sepracor Pharmaceuticals (Ireland) Ltd (represented by: I. Dodds-Smith, solicitor, D. Anderson QC, and J. Stratford, barrister)
Other party to the proceedings: European Commission (represented by: M. Wilderspin and M. Šimerdová, acting as Agents)
Re:
Appeal brought against the order of the General Court (Fourth Chamber) of 4 July 2011 in Case T-275/09 P Sepracor Pharmaceuticals v Commission, dismissing as inadmissible an application for the annulment of the Commission’s decision of 6 May 2009 finding, in the context of the procedure for granting marketing authorisation for the medicinal product ‘Lunivia’, produced by the appellant, that the active substance ‘eszopiclone’, which it contains, does not constitute a new active substance within the meaning of Article 3(2)(a) of Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ 2004 L 136, p. 1) — Concept of actionable measure
Operative part of the order
1.The appeal is dismissed.
2.Sepracor Pharmaceuticals Ltd is ordered to pay the costs.
(<a id="ntr1-C_2012303EN.01000601-E0001" href="#ntc1-C_2012303EN.01000601-E0001">(<span class="super">1</span>)</a> <a href="./../../../../legal-content/EN/AUTO/?uri=OJ:C:2011:347:TOC">OJ C 347, 26.11.2011</a>.)
Language of the case: English